Medical Doctor Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Noubar Ouzounian

Plastic Surgery within the Head & Neck Anaheim, CA Medical Doctor

NPI 1669549515 CMS profile 951777

441 N Lakeview Ave, Anaheim, CA 92807

Open in the dashboard

General payments

$111

3 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Noubar Ouzounian of Anaheim, CA is reported in the CMS Open Payments database as having received $111 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 11th percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $46 1
2022 General $38 1
2021 General $26 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noubar Ouzounian
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Noubar Ouzounian were reported at $0. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Noubar Ouzounian Plastic Surgery within the Head & Neck median Middle half National median
2019 $0 $200 $82–$550 $163
2020 $0 $120 $46–$330 $114
2021 $26 $166 $60–$382 $132
2022 $38 $208 $83–$530 $149
2023 $46 $202 $77–$538 $160
2024 $0 $260 $99–$645 $164
2025 $0 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Medtronic, Inc. $85 2 payments
  2. Intersect ENT, Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $111 3 payments
Products named General payments · program years 2021–2023
  1. PROPEL Otolaryngology (Ear, Nose, Throat) $85 2 payments
  2. PROPEL Otolaryngology (Ear, Nose, Throat) $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

337

Median for Otolaryngology: 297

Drug cost

$9,871

Median for Otolaryngology: $6,314

Branded share of claims

28.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Alvesco Ciclesonide Brand 19 $4,006
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 53 $991
Ipratropium Bromide Generic 45 $964
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 25 $723
Mometasone Furoate Generic 23 $666
Ofloxacin Generic 22 $457
Omeprazole Generic 42 $455
Fluocinolone Acetonide Oil Generic 12 $421
Azelastine Hcl Generic 20 $338
Pantoprazole Sodium Generic 24 $274

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record